COVID-19 vaccine from Biological E.,CORBEVAX gets EUA from DCGI for 12-18 age group
DCGI has already approved CORBEVAX for restricted use in emergency situation among adults
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DCGI
DTAB recommends granting licence to manufacture, stock new drugs, jabs under clinical trial
Various industry experts and subject experts are of opinion that if the government approves recommendation of DTAB and DCGI, it…
DCGI gives nod to SII’s proposal to manufacture vaccine against omicron for test and analysis
Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII, had put in an application to the DCGI on 6th January…
Centre places purchase order for five crore doses of Corbevax COVID vaccine each costing Rs 145 sans…
The government is yet to decide on which segment of beneficiaries this new vaccine would be administered
Covaxin granted Emergency Use Listing in 13 countries, says Centre
Minister of Health Bharati Pravin Pawar said in Lok Sabha that Covaxin was granted Emergency Use Listing (EUL) by the national…
DCGI approves single-shot Sputnik Light vaccine for emergency use in India
Dr Reddy’s had submitted its application for approval to the DCGI in December 2021, in addition to data from clinical trial in…
DCGI approves “Conditional Market Authorisation” of Covaxin and Covishield
The approval pathways through this route are fast-tracked with certain conditions to enhance the access to certain pharmaceuticals…
Each dose of Covishield and Covaxin likely to be capped at Rs 275 after getting regular market…
National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines…
Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients
The company will be using its stem cell product, Stempeucel, for conducting the label extension phase-III clinical trial
Bharat Biotech seeks full marketing approval from DCGI for Covaxin
The company, however, is yet to submit the full follow up data of clinical trial of Covaxin to DCGI, a source said.